PAVmed Inc. Amends Lucid Diagnostics Stake Filing
Ticker: LUCD · Form: SC 13D/A · Filed: Dec 12, 2024 · CIK: 1799011
Sentiment: neutral
Topics: ownership-change, sec-filing, amendment
Related Tickers: LUCD
TL;DR
PAVmed Inc. updated its Lucid Diagnostics stake filing - watch for ownership shifts.
AI Summary
PAVmed Inc. filed an amendment (No. 4) to its Schedule 13D on December 12, 2024, concerning its holdings in Lucid Diagnostics Inc. The filing indicates a change in the reporting person's beneficial ownership. Lishan Aklog, M.D., Chairman and CEO of PAVmed Inc., is listed as a key individual.
Why It Matters
This filing provides updated information on significant ownership changes or intentions regarding Lucid Diagnostics Inc., which could impact its stock price and strategic direction.
Risk Assessment
Risk Level: medium — Schedule 13D filings often signal potential activist investor activity or significant changes in control, which can introduce volatility.
Key Players & Entities
- PAVmed Inc. (company) — Reporting person filing amendment
- Lucid Diagnostics Inc. (company) — Subject company
- Lishan Aklog, M.D. (person) — Chairman and Chief Executive Officer of PAVmed Inc.
FAQ
What specific changes in beneficial ownership are detailed in this amendment?
The filing is an amendment (No. 4) to Schedule 13D, indicating a change in the reporting person's beneficial ownership, but the exact percentage or number of shares is not detailed in the provided text.
Who is the primary reporting person for this filing?
PAVmed Inc. is the filing entity, with Lishan Aklog, M.D., Chairman and CEO of PAVmed Inc., listed as a key individual.
What is the CUSIP number for Lucid Diagnostics Inc. common stock?
The CUSIP number for Lucid Diagnostics Inc. common stock is 54948X 109.
When was this amendment filed with the SEC?
This amendment was filed on December 12, 2024.
What is the business address listed for PAVmed Inc. and Lucid Diagnostics Inc.?
The business address for both PAVmed Inc. and Lucid Diagnostics Inc. is 360 Madison Avenue, 25th Floor, New York, NY 10017.
Filing Stats: 2,174 words · 9 min read · ~7 pages · Grade level 9.4 · Accepted 2024-12-12 16:30:32
Key Financial Figures
- $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti
- $1.25 — of Common Stock at an exercise price of $1.25 per share, with each such stock option
- $148,549 — ions for an aggregate purchase price of $148,549, or approximately $0.874 per share. Mr.
- $0.874 — ase price of $148,549, or approximately $0.874 per share. Mr. Glennon used his persona
- $21.98 million — 2024, the Issuer closed on the sale of $21.98 million in principal amount of Senior Secured C
Filing Documents
- formsc13da.htm (SC 13D/A) — 73KB
- 0001493152-24-049793.txt ( ) — 75KB
Signatures
Signatures After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. PAVMED INC. Dated: December 12, 2024 By: /s/ Lishan Aklog Lishan Aklog, M.D. Chief Executive Officer